A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy

PURPOSE: To evaluate the toxicity, pharmacological, and biological properties of the combination of bortezomib, etoposide, and carboplatin in adults with advanced solid malignancies. PATIENTS AND METHODS: Patients received escalating doses of bortezomib, etoposide, and carboplatin every 21 days. Sur...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lieu, Christopher, Chow, Laura, Pierson, A. Scott, Eckhardt, S. Gail, O'Bryant, Cindy L., Morrow, Mark, Tran, Zung Vu, Wright, John J., Gore, Lia
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2829404/
https://ncbi.nlm.nih.gov/pubmed/18618082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-008-9154-z
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares